Glaukos (NYSE:GKOS) said today it won a nod from the FDA for an investigational new drug Phase II study of its Travoprost intraocular implant utilizing the company’s iDose delivery system for patients with glaucoma. The iDose system is injected through a clear corneal incision and secured in the anterior chamber to continuously elute therapeutic levels of […]
Glaukos (NYSE:GKOS) said it submitted an Investigational New Drug application to the FDA for its Travoprost intraocular implant delivered with the company’s iDose delivery system to reduce elevated intraocular pressure in patients with glaucoma. The Travoprost intraocular implant is injected through a clear corneal incision and secured in the anterior chamber, where the iDose system provides […]
Glaukos (NYSE:GKOS) today released data from a 3-year study of its iStent travecular micro-bypass stent, touting sustained reductions in intra-ocular pressure after treatment with 2 of the devices. The study was published in the November issue of the Clinical Ophtalmology journal, the company said. The iStent trabecular micro-bypass stent is a tiny titanium stent designed to […]
Glaukos (NYSE:GKOS) said yesterday that it agreed to settle a patent infringement lawsuit brought by eye stent rival Transcend Medical. The agreement, in which both sides agree not to sue for patent infringement, calls for Transcend to pay a 1% royalty on sales of its Cy-Pass micro-stent until April 2022, with the total amount capped at $6 […]
A federal judge last week said a jury will decide whether Glaukos (NYSE:GKOS) tried to hide the role of 1 of the inventors of its eye stent in patent filings, in a lawsuit with rival Transcend Medical. In 3 decisions issued Sept. 18, Judge Mitchell Goldberg of the U.S. District Court for Delaware ruled that Transcend’s CyPass device does not infringe the Glaukos […]
Glaukos (NYSE:GKOS) yesterday reported widening losses during its 2nd quarter, but shares held on for the glaucoma-treatment focused company. Laguna Hills, Calif.-based Glaukos reported losses of $32.5 million, or $10.96 per share, on sales of $17.8 million for the 3 months ended June 30. That amounts to a whopping 1000% plus increase in losses on sales […]
Glaukos (NYSE:GKOS) said today it won approval from Health Canada for its iStent Inject trabecular micro-bypass stent designed for use in cataract surgeries to treat glaucoma. The newly cleared iStent inject is indicated for micro-invasive glaucoma surgery procedures to reduce intraocular pressure in patients with primary open-angle glaucoma, pseudoexfoliative glaucoma or pigmentary glaucoma, the Laguna Hills, […]
Glaukos (NYSE:GKOS) said today it won approval from the Australian Therapeutic Goods Administration for its iStent Inject trabecular micro-bypass stent designed for use in cataract surgeries to treat glaucoma. The device is indicated for the reduction of intraocular pressure in adult patients with mild-to-moderate glaucoma who are currently being treated with ocular hypotensive medication, the Laguna […]
Glaukos (NYSE:GKOS) yesterday said it closed its $140 million initial public offering with it underwriters exercising their over-allotment option, meaning net proceeds for the glaucoma device maker of roughly $112.3 million. Laguna Hills, Calif.-based Glaukos said J.P. Morgan, BofA Merrill Lynch and Goldman, Sachs & Co. acted as joint book-running managers, with William Blair and Cantor Fitzgerald […]
Glaukos today raised the proposed price range on its pending initial public offering, saying it will offer 6 million shares at $16 to $17 apiece, which at the midpoint would fetch $99.0 million. In May, Laguna Hills, Calif.-based Glaukos initially said the offering could gross as much as $86.2 million. Earlier this month the company said it planned […]
Glaukos yesterday registered for an initial public offering worth as much as $86.2 million.
The iStent made by Laguna Hills, Calif.-based Glaukos was the 1st micro-invasive glaucoma surgery device to hit the U.S. market. It’s a tiny titanium stent designed to alleviate the intra-ocular pressure caused by glaucoma.